Cargando…
Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252357/ http://dx.doi.org/10.1016/S0168-8278(22)01067-4 |
| _version_ | 1784740245615411200 |
|---|---|
| author | Rosales Renteria, Luis Alejandro Jaramillo-Ramírez, Hiram Calderón-Mendieta, Francisco Camacho-Escobedo, Jesús Avendaño-Reyes, José Manuel López-Rubio, Diana Laura Araiza, Adrián Sández Reyes-Higuera, Gisel Estefania Soto-González, Dulce Renée Arzola-Renteria, Erikc Jesús |
| author_facet | Rosales Renteria, Luis Alejandro Jaramillo-Ramírez, Hiram Calderón-Mendieta, Francisco Camacho-Escobedo, Jesús Avendaño-Reyes, José Manuel López-Rubio, Diana Laura Araiza, Adrián Sández Reyes-Higuera, Gisel Estefania Soto-González, Dulce Renée Arzola-Renteria, Erikc Jesús |
| author_sort | Rosales Renteria, Luis Alejandro |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9252357 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Association for the Study of the Liver. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92523572022-07-05 Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. Rosales Renteria, Luis Alejandro Jaramillo-Ramírez, Hiram Calderón-Mendieta, Francisco Camacho-Escobedo, Jesús Avendaño-Reyes, José Manuel López-Rubio, Diana Laura Araiza, Adrián Sández Reyes-Higuera, Gisel Estefania Soto-González, Dulce Renée Arzola-Renteria, Erikc Jesús J Hepatol POSTER PRESENTATIONS: Thursday 23 June: Cirrhosis and its complications: ACLF and Critical illness European Association for the Study of the Liver. Published by Elsevier B.V. 2022-07 2022-07-04 /pmc/articles/PMC9252357/ http://dx.doi.org/10.1016/S0168-8278(22)01067-4 Text en Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | POSTER PRESENTATIONS: Thursday 23 June: Cirrhosis and its complications: ACLF and Critical illness Rosales Renteria, Luis Alejandro Jaramillo-Ramírez, Hiram Calderón-Mendieta, Francisco Camacho-Escobedo, Jesús Avendaño-Reyes, José Manuel López-Rubio, Diana Laura Araiza, Adrián Sández Reyes-Higuera, Gisel Estefania Soto-González, Dulce Renée Arzola-Renteria, Erikc Jesús Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title | Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title_full | Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title_fullStr | Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title_full_unstemmed | Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title_short | Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| title_sort | use of tocilizumab in patients with stable chronic liver disease and severe covid-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial. |
| topic | POSTER PRESENTATIONS: Thursday 23 June: Cirrhosis and its complications: ACLF and Critical illness |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252357/ http://dx.doi.org/10.1016/S0168-8278(22)01067-4 |
| work_keys_str_mv | AT rosalesrenterialuisalejandro useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT jaramilloramirezhiram useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT calderonmendietafrancisco useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT camachoescobedojesus useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT avendanoreyesjosemanuel useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT lopezrubiodianalaura useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT araizaadriansandez useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT reyeshigueragiselestefania useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT sotogonzalezdulcerenee useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial AT arzolarenteriaerikcjesus useoftocilizumabinpatientswithstablechronicliverdiseaseandseverecovid19forpreventionofdecompensatedcirrhosisaprospectiveopenlabelrandomizedcontrolledtrial |